pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-3820Research ArticleМАКСАВИН (ЛОМЕФЛОКСАЦИН) — МЕЖДУНАРОДНЫЙ ОПЫТ ЭКСПЕРИМЕНТАЛЬНОГО И КЛИНИЧЕСКОГО ИЗУЧЕНИЯ; МАТЕРИАЛ ПОДГОТОВЛЕН СПЕЦИАЛИСТАМИ ФИРМЫ “SEARIE”MAXAGUIN (LOMEFLOXACN): INTERNATIONAL EXPEIENCE OF EXPERIMENTAL AND CLINICAL STUDIES/ THE MATERIALS PROVIDED BY SEARLE’S SPECIALISTSКлиническая эффективность МаксаквинаClinical efficacy of MaxaquinРедакционнаяCтатьяEditorialArticle19932704202200Приложение3136Copyright © Редакционная C., 20222022Редакционная C.Editorial A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3820
.
.
ReferencesСтруктура и антибактериальная активность Максаквина / / Пульмонология.— 1993.— Приложение 1.Структура и антибактериальная активность Максаквина / / Пульмонология.— 1993.— Приложение 1.Mciyer K.U., Ella l J.A . Lomefloxacin microbiologic assessment and unique properties / / Am. J. Med.— 1992.— Vol. 92, SuppM A .— P. 58S— 62S.Mciyer K.U., Ella l J.A . Lomefloxacin microbiologic assessment and unique properties / / Am. J. Med.— 1992.— Vol. 92, SuppM A .— P. 58S— 62S.Фармакокинетические свойства Максаквина / / Пульмонология.— 1993.— Приложение 1.Фармакокинетические свойства Максаквина / / Пульмонология.— 1993.— Приложение 1.Применение Максаквина для лечения и профилактики ин фекций мочевыводящих путей / / Там же.Применение Максаквина для лечения и профилактики ин фекций мочевыводящих путей / / Там же.Максаквин при лечении обострений хронического бронхита / / Там же.Максаквин при лечении обострений хронического бронхита / / Там же.. Amaya-Tapia G., Andrade-Villanueva J., Flores-Glaxiola A. et al. Safety and efficacy of lomefloxacin and cefaclor in the treatm ent of skin and skin structure infections / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 55— 60.. Amaya-Tapia G., Andrade-Villanueva J., Flores-Glaxiola A. et al. Safety and efficacy of lomefloxacin and cefaclor in the treatm ent of skin and skin structure infections / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 55— 60.Seto W .-IL, Lau F.L., Gotuzzo E .IL , Carrillo C. Lomefloxacin versus trim cthoprim /sulfamethovazole in the treatm ent of adults with acute bacterial diarrhea / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 61— 66.Seto W .-IL, Lau F.L., Gotuzzo E .IL , Carrillo C. Lomefloxacin versus trim cthoprim /sulfamethovazole in the treatm ent of adults with acute bacterial diarrhea / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 61— 66.. Rizk E. A worldwide clinical overview of lomefloxacin, a oncedaily fluoroquinolone / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2 .— P. 67— 68.. Rizk E. A worldwide clinical overview of lomefloxacin, a oncedaily fluoroquinolone / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2 .— P. 67— 68.Gotuzzo E ., Carrillo C .t Seas C. et al. Treatm ent of severe cholera with lomefloxacin once-a-day / / Program and Abstracts of the 4th International Symposium on New Quinolones.— Munich, 1992.— P. 353.— Abstract 258.Gotuzzo E ., Carrillo C .t Seas C. et al. Treatm ent of severe cholera with lomefloxacin once-a-day / / Program and Abstracts of the 4th International Symposium on New Quinolones.— Munich, 1992.— P. 353.— Abstract 258.Carrillo C., Tolmos J., Adachi J. et al. In vitro antimicrobial susceptibility testing of 319 toxigenic Vibrio cholerae 01, ElTor, strains isolated during the cholera outbreak in Peru, comparing with 204 isolates of Shigella sp. / / Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.— W ashington: American Society for Microbiology, 1992.— P. 242.— Abstract 793.Carrillo C., Tolmos J., Adachi J. et al. In vitro antimicrobial susceptibility testing of 319 toxigenic Vibrio cholerae 01, ElTor, strains isolated during the cholera outbreak in Peru, comparing with 204 isolates of Shigella sp. / / Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.— W ashington: American Society for Microbiology, 1992.— P. 242.— Abstract 793.Gentry L.O ., Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatm ent of serious gram-negative infections of the skin and skin structure / / Am. J. Med.— 1989.— Vol. 87.— P. 132S— 135S.Gentry L.O ., Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatm ent of serious gram-negative infections of the skin and skin structure / / Am. J. Med.— 1989.— Vol. 87.— P. 132S— 135S.Quintero-Perez N .P., A ndrade-V illanuevaJ.F ., Leon-Garnica G. et al. Efficacy and safety of intravenous ciprofloxacin in the treatm ent of serious infections. A comparison with ceftazidime / / Ibid.— Vol. 87, Suppl.5A.— P. 198— 201.Quintero-Perez N .P., A ndrade-V illanuevaJ.F ., Leon-Garnica G. et al. Efficacy and safety of intravenous ciprofloxacin in the treatm ent of serious infections. A comparison with ceftazidime / / Ibid.— Vol. 87, Suppl.5A.— P. 198— 201.Parish L.C ., Asper R. Systemic treatm ent of cutaneous infections: a comparative study of ciprofloxacin and cefotaxime / / Ibid.— 1987.— Vol. 82, Suppl.4A.— P. 239— 241. ’Parish L.C ., Asper R. Systemic treatm ent of cutaneous infections: a comparative study of ciprofloxacin and cefotaxime / / Ibid.— 1987.— Vol. 82, Suppl.4A.— P. 239— 241. ’Perez- Ruvalcaba V.A., Q uintero-Perez N .P., M orales-Reyes J.J. et al. Double-blind comparison of ciprofloxacin with cefotaxime in the treatm ent of skin and skin structure infections / / Ibid.— P. 242— 246.Perez- Ruvalcaba V.A., Q uintero-Perez N .P., M orales-Reyes J.J. et al. Double-blind comparison of ciprofloxacin with cefotaxime in the treatm ent of skin and skin structure infections / / Ibid.— P. 242— 246.Ramirez-Ronda C .IL, Saavedra S., Rivera-Vazqucz C.R. Comparative double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections / / Ibid.— P. 220— 223.Ramirez-Ronda C .IL, Saavedra S., Rivera-Vazqucz C.R. Comparative double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections / / Ibid.— P. 220— 223.Self P.L., Zelojf B .A ., Sollo D., Gentry L.O. Use of ciprofloxacin in the treatment of serious skin and skin structure infections / / Ibid.— P. 239— 241.Self P.L., Zelojf B .A ., Sollo D., Gentry L.O. Use of ciprofloxacin in the treatment of serious skin and skin structure infections / / Ibid.— P. 239— 241.DuPont II.L ., Edelman R ., Kimmey M . Infectious diarrhea from E.coli to Vibrio / / Patient Care.— 1991.— P. 18— 43.DuPont II.L ., Edelman R ., Kimmey M . Infectious diarrhea from E.coli to Vibrio / / Patient Care.— 1991.— P. 18— 43.DuPont ILL .,Ericsson C.D., Robinson A., Johnson P.C. Current problems in antimicrobial therapy for bacterial enteric ifection / / Am. J. Med.— 1987.— Vol. 82, SuppI.4A.— P. 324— 327.DuPont ILL .,Ericsson C.D., Robinson A., Johnson P.C. Current problems in antimicrobial therapy for bacterial enteric ifection / / Am. J. Med.— 1987.— Vol. 82, SuppI.4A.— P. 324— 327.Bhattacharya D ., Sen G., N air G.B. et al. Multiple drug-resistant Shigella dysenteriae Type 1 and travellers’ diarrhea III. Infect. Dis.— 1986.— Vol. 154.— P. 729—730.Bhattacharya D ., Sen G., N air G.B. et al. Multiple drug-resistant Shigella dysenteriae Type 1 and travellers’ diarrhea III. Infect. Dis.— 1986.— Vol. 154.— P. 729—730.Murray B.E. Resistance of Shigella, Salmonella and other selected enteric pathogens to antimicrobial agents / / Rev. Infect. Dis.— 1986.— Vol. 8 , Suppl.2.— P. S I 72— S181.Murray B.E. Resistance of Shigella, Salmonella and other selected enteric pathogens to antimicrobial agents / / Rev. Infect. Dis.— 1986.— Vol. 8 , Suppl.2.— P. S I 72— S181.RogerieF., O ttD ., Vandepitte J. e ta l. Comparison of norfloxacin and nalidixic acid for treatm ent of dysentery caused by Shigella dysenteriae Type 1 in adults / / Antimicrob. Agents Chemother.— 1986.— Vol. 28.— P. 883— 886.RogerieF., O ttD ., Vandepitte J. e ta l. Comparison of norfloxacin and nalidixic acid for treatm ent of dysentery caused by Shigella dysenteriae Type 1 in adults / / Antimicrob. Agents Chemother.— 1986.— Vol. 28.— P. 883— 886.Bose R ., Nashipuri J.N . Sen P.K. et al. Epidemic of disentery in West Bengal: clinician’s enigma / / Lancet.— 1984.— Vol. 2.— P. 1160.Bose R ., Nashipuri J.N . Sen P.K. et al. Epidemic of disentery in West Bengal: clinician’s enigma / / Lancet.— 1984.— Vol. 2.— P. 1160.Bennish M .E , Salam M .A ., Haider M .A ., Barza M . Therapy for shigellosis II. Randomized, double-blind comparison of ciprofloxacin and ampicillin / / J. Infect. Dis.— 1990.— Vol. 162.— P. 711— 716.Bennish M .E , Salam M .A ., Haider M .A ., Barza M . Therapy for shigellosis II. Randomized, double-blind comparison of ciprofloxacin and ampicillin / / J. Infect. Dis.— 1990.— Vol. 162.— P. 711— 716.Goodman L.J., Trenholm e G.M., Kaplan R.L. et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults / / Arch. Intern. Med.— 1990— Vol. 150.— P. 541—546.Goodman L.J., Trenholm e G.M., Kaplan R.L. et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults / / Arch. Intern. Med.— 1990— Vol. 150.— P. 541—546.Gotuzzo E ., Oberhelman R.A., Maguina C. et al. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim- sulfamethoxazole for acute shegellosis in adults / / Antimicrob. Agents Chemother.— 1989.— Vol. 33.— P. 1101 — 1104.Gotuzzo E ., Oberhelman R.A., Maguina C. et al. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim- sulfamethoxazole for acute shegellosis in adults / / Antimicrob. Agents Chemother.— 1989.— Vol. 33.— P. 1101 — 1104.Imagawa Y., Tomizawa L , Takizawa Y. et al. Comparison of clinical efficacy of ciprofloxacin (C PEX , BAY 0 9867) and pipemidic acid (PPA) in the treatm ent of infectious enteritis by a double-blind method / / Kansenshogaku Zasshi.— 1988.— Vol. 62.— P. 322— 339.Imagawa Y., Tomizawa L , Takizawa Y. et al. Comparison of clinical efficacy of ciprofloxacin (C PEX , BAY 0 9867) and pipemidic acid (PPA) in the treatm ent of infectious enteritis by a double-blind method / / Kansenshogaku Zasshi.— 1988.— Vol. 62.— P. 322— 339.Lolekha S., Patanachareon S., Thanangkul B., Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatm ent of acute bacterial diarrhea: a placebo-controlled study / / Scand. J. Infect. Dis.— 1988.— Vol. 56, Suppl.— P. 34— 35.Lolekha S., Patanachareon S., Thanangkul B., Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatm ent of acute bacterial diarrhea: a placebo-controlled study / / Scand. J. Infect. Dis.— 1988.— Vol. 56, Suppl.— P. 34— 35.DeMol P., Mets T., Vandepitte J. et al. Treatm ent of bacillary dysentery: a comparison between enoxacin and nalidixic acid I I J. Antimicrob. Chemother.— 1987.— Vol. 19.— P. 695— 698.DeMol P., Mets T., Vandepitte J. et al. Treatm ent of bacillary dysentery: a comparison between enoxacin and nalidixic acid I I J. Antimicrob. Chemother.— 1987.— Vol. 19.— P. 695— 698.DuPont I L L , Corrado M .L , Sabbaj J. Use of norfloxacin in the treatm ent of acute diarrheal disease / / Am. J. Med.— 1987.— Vol. 82, Suppl.6B .— P. 79— 83.DuPont I L L , Corrado M .L , Sabbaj J. Use of norfloxacin in the treatm ent of acute diarrheal disease / / Am. J. Med.— 1987.— Vol. 82, Suppl.6B .— P. 79— 83.Ericsson C.D., Johnson P.C., DuPont I I .L et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for traveller’s diarrhea / / Ann. Intern. Med.— 1987.— Vol. 106.— P. 216— 220.Ericsson C.D., Johnson P.C., DuPont I I .L et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for traveller’s diarrhea / / Ann. Intern. Med.— 1987.— Vol. 106.— P. 216— 220.Pichler II.E ., Dirid I G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea / / Am. J. Med.— 1987.— Vol. 82, Suppl.4A.— P. 329— 332.Pichler II.E ., Dirid I G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea / / Am. J. Med.— 1987.— Vol. 82, Suppl.4A.— P. 329— 332.Jones R.N . Fluoroquinolone (lomefloxacin) international surveillance trial: a report of 30 months of monitoring in vitro activity / / Ibid.— Vol. 92, Suppl.4A.— P. 52S—57S.Jones R.N . Fluoroquinolone (lomefloxacin) international surveillance trial: a report of 30 months of monitoring in vitro activity / / Ibid.— Vol. 92, Suppl.4A.— P. 52S—57S.Felmingham D., Robbins M .J. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens / / Diagn. Microbiol. Infect. Dis.— 1992.— Vol. 15.— P. 339— 343.Felmingham D., Robbins M .J. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens / / Diagn. Microbiol. Infect. Dis.— 1992.— Vol. 15.— P. 339— 343.Butler T., Cartagenova M ., D unn D. Treatm ent of experimental Salmonella typhimurium infection in mice with lomefloxacin / / J.Antimicrob. C hemother.— 1990.— Vol. 25.— P. 629— 634.Butler T., Cartagenova M ., D unn D. Treatm ent of experimental Salmonella typhimurium infection in mice with lomefloxacin / / J.Antimicrob. C hemother.— 1990.— Vol. 25.— P. 629— 634.Dubois J., St-Piere C. A ntibacterial activity of lomefloxacin against urinary tract, gastrointestinal tract, and respiratory tract pathogens / / Curr. Thcr. Res.— 1 9 8 9 .- Vol. 4 5 . - P. 100 0 -1 0 0 5 .Dubois J., St-Piere C. A ntibacterial activity of lomefloxacin against urinary tract, gastrointestinal tract, and respiratory tract pathogens / / Curr. Thcr. Res.— 1 9 8 9 .- Vol. 4 5 . - P. 100 0 -1 0 0 5 .Segreti J., Nelson J.A ., Goodman L.J. el al. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea / / Antimicrob. Agents Chemother.— 1989.— Vol. 3 3 .— P. 1385— 1387.Segreti J., Nelson J.A ., Goodman L.J. el al. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea / / Antimicrob. Agents Chemother.— 1989.— Vol. 3 3 .— P. 1385— 1387.Doutsu Y., Inone Y., Masaki M . et al. Laboratory and clinical studies on NY-198 / / Chemotherapy (Tokyo).— 1988.— Vol. 36, Suppl.2.— P. 745— 762.Doutsu Y., Inone Y., Masaki M . et al. Laboratory and clinical studies on NY-198 / / Chemotherapy (Tokyo).— 1988.— Vol. 36, Suppl.2.— P. 745— 762.Leroy A ., Ilambert G., Fillasire J.-P ., Grise P. Penetration of lomefloxacin into human prostatic tissue / / Am. J. Med.— 1992.— Vol. 92, Suppl.4a.— P. 12S— 14S.Leroy A ., Ilambert G., Fillasire J.-P ., Grise P. Penetration of lomefloxacin into human prostatic tissue / / Am. J. Med.— 1992.— Vol. 92, Suppl.4a.— P. 12S— 14S.Klim berg L W ., Childs S.J., Madore R .J., Kl.imbc.rg S.R. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery / / Ibid.— P. 121S— 125S.Klim berg L W ., Childs S.J., Madore R .J., Kl.imbc.rg S.R. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery / / Ibid.— P. 121S— 125S.Kovarik J.M ., de Hond J.A .P .M ., Iloepelman I.M . et al. Intraprostatic distribution of lomefloxacin following multiple-dose administration / / Antimicrob. Agents Chemother.— 1990.— Vol. 34.— P. 2398— 2401.Kovarik J.M ., de Hond J.A .P .M ., Iloepelman I.M . et al. Intraprostatic distribution of lomefloxacin following multiple-dose administration / / Antimicrob. Agents Chemother.— 1990.— Vol. 34.— P. 2398— 2401..On A ., N ightingale C .IL , Q uintiliani R. et al. Lomefloxacin concentrations in bone after a single oral dose / / Am. J. Med.— 1992.— Vol. 92, Suppl.4Л.— P. 15S— 17S..On A ., N ightingale C .IL , Q uintiliani R. et al. Lomefloxacin concentrations in bone after a single oral dose / / Am. J. Med.— 1992.— Vol. 92, Suppl.4Л.— P. 15S— 17S.Woodworth J., F itzsimmons S. Lomefloxacin pharm acokinetics in young and elderly subjects / / Program and Abstracts of the Twenty-Ninth Intersciencc Conference on Antimicrobial Agents and C hem otherapy.— Washington: American Society for Micobiologv, 1989.— P. 316.— A bstract 1268.Woodworth J., F itzsimmons S. Lomefloxacin pharm acokinetics in young and elderly subjects / / Program and Abstracts of the Twenty-Ninth Intersciencc Conference on Antimicrobial Agents and C hem otherapy.— Washington: American Society for Micobiologv, 1989.— P. 316.— A bstract 1268.Crom e P., Morrison P.J. Pharm acokinetics of a single oral dose of lomefloxacin in healthy elderly volunteers / / Drug Invest.— 1 9 9 1 ._ vol. 3.— P. 183— 187.Crom e P., Morrison P.J. Pharm acokinetics of a single oral dose of lomefloxacin in healthy elderly volunteers / / Drug Invest.— 1 9 9 1 ._ vol. 3.— P. 183— 187.Schentag J.J., Goss T.F. Quinolone pharmacokinetics in the elderly / / Am. J. Med.— 1992.— Vol. 92, Suppl.4A.— P. 33S— 37S.Schentag J.J., Goss T.F. Quinolone pharmacokinetics in the elderly / / Am. J. Med.— 1992.— Vol. 92, Suppl.4A.— P. 33S— 37S.Crom P., Brucc-Jones P. Infection in the elderly: studies with lomefloxacin / / Ibid.— P. 126S— 129S.Crom P., Brucc-Jones P. Infection in the elderly: studies with lomefloxacin / / Ibid.— P. 126S— 129S.
The authors declare that there are no conflicts of interest present.